BEAM Beam Therapeutics Inc.

Nasdaq beamtx.com


$ 27.95 $ -0.24 (-0.85 %)    

Friday, 24-Oct-2025 19:01:53 EDT
QQQ $ 617.50 $ 6.52 (1.07 %)
DIA $ 472.45 $ 4.92 (1.05 %)
SPY $ 677.25 $ 5.49 (0.82 %)
TLT $ 91.47 $ 0.04 (0.04 %)
GLD $ 378.59 $ -1.27 (-0.34 %)
$ 27.96
$ 28.69
$ 27.60 x 50
$ 28.79 x 1
-- - --
$ 13.53 - $ 35.25
1,549,898
na
2.83B
$ 1.95
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-05-2025 06-30-2025 10-Q
2 05-06-2025 03-31-2025 10-Q
3 02-25-2025 12-31-2024 10-K
4 11-05-2024 09-30-2024 10-Q
5 08-06-2024 06-30-2024 10-Q
6 05-07-2024 03-31-2024 10-Q
7 02-27-2024 12-31-2023 10-K
8 11-08-2023 09-30-2023 10-Q
9 08-08-2023 06-30-2023 10-Q
10 05-10-2023 03-31-2023 10-Q
11 02-28-2023 12-31-2022 10-K
12 11-07-2022 09-30-2022 10-Q
13 08-09-2022 06-30-2022 10-Q
14 05-09-2022 03-31-2022 10-Q
15 02-28-2022 12-31-2021 10-K
16 11-08-2021 09-30-2021 10-Q
17 08-10-2021 06-30-2021 10-Q
18 05-11-2021 03-31-2021 10-Q
19 03-15-2021 12-31-2020 10-K
20 11-10-2020 09-30-2020 10-Q
21 08-12-2020 06-30-2020 10-Q
22 05-12-2020 03-31-2020 10-Q
23 03-30-2020 12-31-2019 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 hc-wainwright--co-reiterates-buy-on-beam-therapeutics-maintains-80-price-target

HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Beam Therapeutics (NASDAQ:BEAM) with a Buy and maintains $80 ...

 jim-cramer-sees-more-upside-for-shopify-likes-coreweaves-ai-moves

Jim Cramer recommends buying Affirm Holdings (AFRM) on CNBC's Mad Money Lightning Round. Analysts also support Beam Therape...

 my-top-biotech-stock-picks-and-portfolio-strategy-for-the-next-3-10-years

Forecasts in biotech market indicate that by 2030, gene therapy will become more accessible, potentially generating hundreds of...

 hc-wainwright--co-reiterates-buy-on-beam-therapeutics-maintains-80-price-target

HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Beam Therapeutics (NASDAQ:BEAM) with a Buy and maintains $80 ...

 pfizers-investigational-drug-flunks-late-stage-for-sickle-cell-disease

Pfizer's Phase 3 trial of inclacumab in sickle cell disease misses its main goal but shows safety, with further updates on ...

 barclays-maintains-equal-weight-on-beam-therapeutics-lowers-price-target-to-21

Barclays analyst Gena Wang maintains Beam Therapeutics (NASDAQ:BEAM) with a Equal-Weight and lowers the price target from $2...

 beam-therapeutics-enters-agreement-to-acquire-early-stage-life-sciences-company-for-403128-upfront-shares-and-up-to-89m-in-milestone-payments

On July 1, 2025, Beam Therapeutics Inc. (the "Company") entered into an Agreement and Plan of Merger pursuant to which ...

 cathie-woods-ark-invest-continues-to-offload-coinbase-bets-big-on-sofi-technologies

Cathie Wood-led Ark Invest made notable trades on Friday, including selling shares in Coinbase and Roblox.

 eli-lillys-13-billion-verve-deal-signals-confidence-in-gene-editing-space-analyst

Lilly's Verve acquisition lifts sentiment in gene editing stocks, with analysts calling it a strategic and timely move in a...

 the-fda-has-granted-orphan-drug-designation-to-beam-therapeutics-beam-101-an-investigational-genetically-modified-cell-therapy-for-sickle-cell-disease

Data from seven patients treated with BEAM-101 in the BEACON clinical trial were presented at the 66th American Society of Hema...

 beam-therapeutics-receives-fda-orphan-drug-designation-for-beam-302-a-base-editing-therapy-targeting-alpha-1-antitrypsin-deficiency

Beam Therapeutics Inc. (NASDAQ:BEAM), a biotechnology company developing precision genetic medicines through base editing, toda...

 beam-therapeutics-to-present-new-data-from-beam-101-program-ii-sickle-cell-disease-at-european-hematology-association-2025-congress

Presentation to Include Updated Data from 17 Sickle Cell Disease Patients in the Ongoing BEACON Phase 1/2 Clinical Trial Evalua...

 beam-therapeutics-announces-us-fda-regenerative-medicine-advanced-therapy-designation-has-been-granted-to-beam-302-for-the-treatment-of-alpha-1-antitrypsin-deficiency

Beam Therapeutics Inc. (NASDAQ:BEAM), a biotechnology company developing precision genetic medicines through base editing, toda...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION